Project Grant R01HL176336
Award Date 8/7/26
Completion Date 7/31/30
Dollars Obligated $3M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
San Francisco, CA 94121, USA
Similar Awards
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $2.98 million Project Grant (CFDA 93.837 – Cardiovascular Diseases Research) to the University of California, San Francisco to conduct a four-year research study examining the impact of asymptomatic cytomegalovirus (CMV) infection on cardiovascular event risk in people with HIV (PWH). The primary deliverable is a large-scale Mendelian randomization study that will assess whether CMV-associated plasma proteomic signatures and...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The Regents of the University of California, San Francisco a $3.26 million Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) for a four-year period beginning September 1, 2025. This research initiative investigates immune activation and region-specific myocardial arrhythmic substrate in sudden cardiac death (SCD) victims with HIV. The study builds upon the investigators'...
- The National Institutes of Health National Heart Lung and Blood Institute awarded the Regents of the University of California, San Francisco $813,499 on August 10, 2026, for Project Grant R01HL186881 under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds research investigating immune exhaustion, telomere length, and immune response effects on diffusing capacity for carbon monoxide (DLCO) in people with HIV, termed the I'M TIRED-HIV Study. Preliminary findings show that...
- The National Heart, Lung, and Blood Institute awarded Cedars-Sinai Medical Center $1.379 million on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate cardioprotective mechanisms of Y RNA signaling in macrophages as a potential therapeutic approach to myocardial infarction. The research dissects how a small non-coding RNA called YREX3—secreted by therapeutically-enhanced cardiac stromal cells—signals macrophages to enhance their capacity for...
- The National Institute of Nursing Research awarded a $300,000 cooperative agreement to The Regents of the University of California, San Francisco on July 25, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to establish and operate a Leadership and Coordination Center (LACC) for the MACS/WIHS Combined Cohort Study (MWCCS). The LACC will provide scientific, operational, and administrative oversight of the MWCCS, a longitudinal cohort study following over 5,600 men...
- The National Heart, Lung, and Blood Institute awarded Kaiser Foundation Hospitals $3,302,181 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to assess heart failure risk factors and prediction models in people with HIV through a cohort study in three integrated health systems. The research will compare the impact of traditional and HIV-specific risk factors on incident heart failure among people with HIV and demographically matched people without HIV; evaluate...
- The National Heart, Lung, and Blood Institute awarded $1.555 million to the University of Maryland, Baltimore on August 5, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to model and treat chronic HIV-induced lung infections. The research investigates immune mechanisms underlying increased susceptibility to respiratory infections in people living with HIV. The project focuses on how chronic HIV infection impairs dendritic cell differentiation and function, hypothesizing...
- The National Heart, Lung, and Blood Institute awarded J. David Gladstone Institutes $1,585,727 on September 12, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate epigenomic mechanisms of cardiac fibrosis and heart failure. The project tests the hypothesis that the transcriptional regulator Meox1 functions as a key driver of fibroblast activation, myocardial fibrosis, and heart failure pathogenesis, leveraging novel genetic mouse models, cell lines, and...
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of California, San Francisco $3,093,164 on June 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and validate an expanded HIV Synthesis microsimulation model incorporating hypertension and cardiovascular disease outcomes, evaluate health effects and cost-effectiveness of implementation strategies for HIV-hypertension care integration across West, East, and Southern Africa...
- The National Heart, Lung, and Blood Institute awarded Icahn School of Medicine at Mount Sinai $462,000 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct comparative analysis of thrombogenic risk across menopausal stages in women with HIV. The research examines sex-based differences in cardiovascular disease risk among women with HIV, focusing on how immune activation, platelet reactivity, and age-related changes in sex hormones interact to elevate...